HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Tolmetin

HCID 5509
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
26171-23-3
Standard SMILES
Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
InChIKey
UPSPUYADGBWSHF-UHFFFAOYSA-N
Molecular formula
C15H15NO3
Average molar mass
257.28 g/mol
Monoisotopic mass
257.10519334

Overview

Tolmetin is a monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug. It has a role as a non-steroidal anti-inflammatory drug and an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor. It is a monocarboxylic acid, a member of pyrroles and an aromatic ketone. It is a conjugate acid of a tolmetin(1-).

Names & identifiers

Preferred name
Tolmetin
IUPAC
2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid
English name
Tolmetin
Molecular formula
C15H15NO3
Molecular weight
257.28

Names & synonyms

tolmetin26171-23-31-Methyl-5-p-toluoylpyrrole-2-acetic acidTolmetineTolectinTolmetinaTolmetinumTolmetinoMcN-25591H-Pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)-2-(1-METHYL-5-(4-METHYLBENZOYL)-1H-PYRROL-2-YL)ACETIC ACIDMCN 2559
Show more names
C07149olmetinMethyiinpyrolyzateTolmetin PrecursorTolmetin, 10 mM in DMSO
1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetic acidD8K2JPN18BPyrrole-2-acetic acid, 1-methyl-5-p-toluoyl-DTXSID2043951CHEBI:719415-22-06-00392 (Beilstein Handbook Reference)

Database identifiers

CAS
26171-23-3
PubChem CID
5509
DTXSID
DTXSID2043951
ChEMBL
CHEMBL1020
ChEBI
CHEBI:71941

Properties

Computed structural propertiesFilling in

XLogP
2.8
Topological polar surface area
59.3 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
3
Rotatable bonds
4
Heavy atoms
19
Formal charge
0
Complexity
347

Experimental & physicochemical properties

Drugs · 2 items

DEA NFLIS-Drug Category -> Analgesics

Pharmaceuticals -> Listed in ZINC15

LogP · 2 items

2.6

2.79

Color/FormCRYSTALS FROM ACETONITRILE
Solubility1.31e-01 g/L
Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

Pharmaceuticals

Melting Point · 2 items

155-157 °C (DECOMPOSES)

156 °C

Physical DescriptionSolid
Dissociation Constants · 3 items

3.5

3.5

3.5

Collision Cross Section · 2 items

157.42 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (33.3%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P316, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Other Safety InformationIMAP assessments - 1H-Pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)-: Environment tier I assessment
Special Reports · 3 items

REVIEW ARTICLE INCLUDES TOLMETIN.[SIMON LS, MILLS JA; NONSTEROIDAL ANTIINFLAMMATORY DRUGS (SECOND OF TWO PARTS); N ENGL J MED 302 (22) 1237 (1980)]

TOLMETIN'S PHARMACOLOGICAL PROPERTIES & THERAPEUTIC EFFICACY IN RHEUMATIC DISEASES ARE REVIEWED.[BROGDEN RN ET AL; TOLMETIN: A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES & THERAPEUTIC EFFICACY IN RHEUMATIC DISEASES; DRUGS 15(6) 429 (1978)]

THE HISTORY OF RESEARCH & DEVELOPMENT OF NONSTEROIDAL ANTI-INFLAMMATORY AGENTS, INCL TOLMETIN.[GRINGAUZ A; NONSTEROIDAL ANTI-INFLAMMATORY AGENTS--ANYTHING NEW UNDER THE SUN?; HOSP FORMUL 14(MAR) 290 (1979)]

Hazard Classes and CategoriesAcute Tox. 3 (33.3%)

Toxicology

Interactions · 5 items

PT RECEIVING CORTICOSTEROID OR GOLD THERAPY OBTAINED GREATER RELIEF OF SYMPTOMS WHEN TOLMETIN WAS ADDED TO THE REGIMEN, & THERE WAS EVIDENCE THAT TOLMETIN HAD A STEROID-SPARING EFFECT. /TOLMETIN SODIUM/

Chemistry & industry

Pharmacology

ATC Code · 4 items

M - Musculo-skeletal system

M - Musculo-skeletal system

QM - Musculo-skeletal system

QM - Musculo-skeletal system

Pharmacodynamics · 1 item

Tolmetin is a nonsteroidal anti-inflammatory agent. Studies in animals have shown tolmetin to possess anti-inflammatory, analgesic and antipyretic activity. In the rat, tolmetin prevents the development of experimentally induced polyarthritis and also decreases established inflammation. In patients with either rheumatoid arthritis or osteaoarthritis, tolmetin is as effective as aspirin and indomethacin in controlling disease activity, but the frequency of the milder gastrointestinal adverse effects and tinnitus was less than in aspirin-treated patients, and the incidence of central nervous system adverse effects was less than in indomethacin-treated patients. In patients with juvenile rheumatoid arthritis, tolmetin is as effective as aspirin in controlling disease activity, with a similar incidence of adverse reactions. tolmetin has produced additional therapeutic benefit when added to a regimen of gold salts and, to a lesser extent, with corticosteroids. Tolmetin should not be used in conjunction with salicylates since greater benefit from the combination is not likely, but the potential for adverse reactions is increased.

Mechanism of Action · 3 items

The mode of action of tolmetin is not known. However, studies in laboratory animals and man have demonstrated that the anti-inflammatory action of tolmetin is not due to pituitary-adrenal stimulation. Tolmetin inhibits prostaglandin synthetase in vitro and lowers the plasma level of prostaglandin E in man. This reduction in prostaglandin synthesis may be responsible for the anti-inflammatory action. Tolmetin does not appear to alter the course of the underlying disease in man.

ALTHOUGH IT DIFFERS CHEMICALLY FROM ASPIRIN & OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS, ITS PHARMACOLOGIC PROPERTIES ARE SIMILAR. /TOLMETIN SODIUM/

...INHIBITS PROSTAGLANDIN SYNTHETASE IN VITRO. IT ALSO HAS BEEN SHOWN TO LOWER PLASMA LEVEL OF PROSTAGLANDIN E IN MAN. HOWEVER, SIGNIFICANCE OF THESE ACTIONS IN RELATION TO CLINICAL EFFECTS IS NOT KNOWN. /TOLMETIN SODIUM/

Biological Half-Life

Related reactions

19 records
New reaction record
HRID 286915 reaction equation
HRID 286915As product
HRID 365603 reaction equation
HRID 365603As reactant
HRID 365619 reaction equation
HRID 365619As reactant
HRID 369384 reaction equation
HRID 369384As reactant
HRID 369401 reaction equation
HRID 369401As reactant
HRID 483239 reaction equation
HRID 483239As reactant
HRID 618319 reaction equation
HRID 618319As reactant
HRID 618335 reaction equation
HRID 618335As reactant
PreviousPage 1 of 3

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
UNII
D8K2JPN18B
EC Number
247-497-2
Nikkaji
J20.519B

156.7 Ų [M+H]+ [CCS Type: TW]

Other Experimental PropertiesPYRROLE-ACETIC ACID DERIVATIVE /TOLMETIN SODIUM/

Physicochemical properties

Melting point
156 °C · 156 °C
Boiling point
400.53 °C · 400.53°C (rough estimate)
Density
1.1391 · 1.1391 (rough estimate)
refractive index
1.52 · 1.5200 (estimate)
storage temp.
2 · 2-8°C
solubility
Chloroform (Slightly), Methanol (Slightly)
pka
3.5 · pKa 3.5(H2O t undefined I undefined) (Uncertain)
form
Solid
color
Off-White to Pale Yellow
Water Solubility
222 mg/L · 222 mg/L
InChI
InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)
InChIKey
UPSPUYADGBWSHF-UHFFFAOYSA-N
SMILES
N1(C)C(C(=O)C2=CC=C(C)C=C2)=CC=C1CC(O)=O
FDA UNII
8 K2JPN18B · D8K2JPN18B
ATC code
1 AB03,M02AA21 · M01AB03,M02AA21
NIST Chemistry Reference
Tolmetin(26171-23-3)
EPA Substance Registry System
1 H-Pyrrole-2-acetic · 1H-Pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)- (26171-23-3)
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
315 · H315-H302-H335-H319
Precautionary statements
264 · P264-P280-P305+P351+P338-P337+P313P-P264-P280-P302+P352-P321-P332+P313-P362-P264-P270-P301+P312-P330-P501
Hazardous Substances Data
26171 · 26171-23-3(Hazardous Substances Data)

CONCOMITANT ADMIN OF TOLMETIN & ACETAMINOPHEN PRODUCED A GREATER IMPROVEMENT IN SYMPTOMS THAN WITH TOLMETIN ALONE, BUT FURTHER STUDIES ARE NEEDED TO SUBSTANTIATE THIS EFFECT. /TOLMETIN SODIUM/

CONCOMITANT ASPIRIN REDUCES PLASMA LEVELS OF TOLMETIN BY ABOUT 20%, BUT THE INTERACTION PROBABLY IS NOT CLINICALLY IMPORTANT. /TOLMETIN SODIUM/

IN DOGS, PROSTAGLANDIN SYNTHETASE INHIBITORS INDOMETHACIN & TOLMETIN BLOCKED FUROSEMIDE-INDUCED INCR IN RENIN SECRETION WHETHER FUROSEMIDE WAS GIVEN IV OR INTO RENAL ARTERY.

DESPITE ITS EXTENSIVE BINDING TO ALBUMIN...NO CHANGE IN PROTHROMBIN TIME WHEN WARFARIN & TOLMETIN WERE GIVEN TOGETHER.

HepatotoxicityUp to 5% of patients taking tolmetin chronically experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation. Marked aminotransferase elevations (>3 fold elevated) occur in
Human Toxicity Excerpts · 5 items

MOST FREQUENTLY REPORTED ADVERSE REACTIONS ARE GI DISTURBANCES... EPIGASTRIC DISTRESS, INCL HEARTBURN, DYSPEPSIA, & ABDOMINAL PAIN, WAS MOST COMMON; OTHER REACTIONS INCL NAUSEA, VOMITING, & CONSTIPATION. GI BLEEDING WAS REPORTED OCCASIONALLY... IN CLINICAL STUDIES, PEPTIC ULCER OCCURRED IN APPROX 2% OF PT. /TOLMETIN SODIUM/

CNS REACTIONS REPORTED INCL HEADACHE, DIZZINESS, LIGHTHEADEDNESS, NERVOUSNESS, & DROWSINESS. ... OTHER REACTIONS OBSERVED OCCASIONALLY WERE RASH OR URTICARIA, PRURITUS, TINNITUS, & MILD EDEMA, WHICH WAS RELATED TO SODIUM RETENTION. /TOLMETIN SODIUM/

THE CASE OF A 51-YR-OLD MAN WHO DEVELOPED ANAPHYLAXIS AFTER RESTARTING ORAL THERAPY WITH TOLMETIN SODIUM FOR A PULLED GROIN MUSCLE IS PRESENTED.

A 56-YR-OLD MAN WITH RHEUMATOID ARTHRITIS, BEING TREATED WITH TOLMETIN SODIUM 1800 MG/DAY, DEVELOPED A DRUG FEVER BELIEVED TO BE DUE TO TOLMETIN SODIUM THERAPY.

For more Human Toxicity Excerpts (Complete) data for TOLMETIN (9 total), please visit the HSDB record page.

Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

tolmetin

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Non-Human Toxicity Excerpts · 2 items

MAX ANTIINFLAMMATORY ACTIVITY OF RECTALLY ADMIN TOLMETIN WAS OBSERVED IN RATS AFTER 125 MG/KG DOSE. TOLMETIN ALSO SHOWED GREATER ACTIVITY WHEN ADMIN RECTALLY THAN ORALLY. THE LD50 OF RECTALLY ADMIN TOLMETIN WAS 743.6 MG/KG IN MALE & 843.4 MG/KG IN FEMALE RATS.

TOLMETIN (100-150 MUG/L) DOSE-DEPENDENTLY INHIBITED DNA SYNTHESIS BY MOUSE SPLEEN CELLS & HUMAN LYMPHOCYTES IN VITRO.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H315-H302-H335-H319
Precautionary statements
P264-P280-P305+P351+P338-P337+P313P-P264-P280-P302+P352-P321-P332+P313-P362-P264-P270-P301+P312-P330-P501
Hazardous Substances Data
26171-23-3(Hazardous Substances Data)
Biphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.
Metabolism/Metabolites · 3 items

Essentially all of the administered dose is recovered in the urine in 24 hours either as an inactive oxidative metabolite or as conjugates of tolmetin.

URINE METABOLITES 1-METHYL-5-(4-CARBOXYBENZOYL)-1H-PYRROLE-2-ACETIC ACID & TOLMETIN GLUCURONIDE NOTED AFTER TOLMETIN SODIUM.

Tolmetin has known human metabolites that include Tolmetin glucuronide.

FDA Pharmacological Classification · 6 items

D8K2JPN18B

TOLMETIN

Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors

Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal

Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug

Tolmetin is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of tolmetin is as a Cyclooxygenase Inhibitor.

MeSH Pharmacological Classification · 2 items

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Absorption, Distribution and Excretion · 6 items

Rapidly and almost completely absorbed with peak plasma levels being reached within 30-60 minutes after an oral therapeutic dose.

THE DRUG IS RAPIDLY ABSORBED AFTER ORAL ADMIN, PEAK PLASMA LEVELS OCCUR IN 30 TO 60 MIN. IT IS EXCRETED LARGELY IN URINE, PRIMARILY AS CONJUGATES OR METABOLITES. ITS PLASMA HALF-LIFE IS APPROX 1 HR. /TOLMETIN SODIUM/

GI ABSORPTION IS ABOUT 90% OR GREATER...WITH PEAK LEVELS WITHIN 20-60 MIN FOR TOLMETIN... PROTEIN BINDING IS EXTENSIVE, BEING 90% OR GREATER... HEPATIC BIOTRANSFORMATION & RENAL EXCRETION WITH SOME FECAL EXCRETION OF METABOLITES ARE THE MEANS OF ELIMINATION. /TOLMETIN SODIUM/

TOLMETIN IS RAPIDLY & COMPLETELY ABSORBED FOLLOWING ORAL ADMIN TO MAN, & CONCN ACHIEVED IN PLASMA ARE NOT REDUCED BY CONCOMITANT ADMIN OF GASTRIC ANTACIDS. PEAK CONCN ARE ACHIEVED 20-60 MIN AFTER ORAL ADMIN, & T/2 IN PLASMA IS BETWEEN 1 & 3 HR.

AFTER ABSORPTION, TOLMETIN IS EXTENSIVELY (99%) BOUND TO PLASMA PROTEINS. VIRTUALLY ALL OF THE DRUG CAN BE RECOVERED IN URINE AFTER 24 HR; SOME IS UNCHANGED (17%), BUT MOST IS CONJUGATED (10%) OR OTHERWISE METABOLIZED. THE MAJOR METABOLITE TRANSFORMATION IS DECARBOXYLATION.

TOLMETIN SODIUM WAS RAPIDLY & COMPLETELY ABSORBED (PEAK TIME, 20-60 MIN) & ELIMINATED RAPIDLY FROM PLASMA WITH BIPHASIC DECAY CURVE & ELIMINATION T/2 OF APPROX 2.1 HR.

Cellular LocationsCytoplasm
Metabolite PathwaysTolmetin Action Pathway

Uses & manufacturing

UsesMEDICATION
Methods of ManufacturingCARSON, FRENCH PATENT 1,574,570 (1969 TO MCNEIL LABS), CA 72, 100498Y (1969). PHARMACOLOGY: CARSON ET AL, J MED CHEM 14, 646 (1971); WONG ET AL, J PHARMACOL EXP THER 185, 127 (1973).
Formulations/PreparationsTOLECTIN (MCNEIL), ORAL: TABLETS 200 MG. /TOLMETIN SODIUM/
Use ClassificationPharmaceuticals
Applications · 4 items

DescriptionAn antiinflammatory, analgesic, and antipyretic that is as efficacious as moderate doses of aspirin and better tolerated. Tolmetin produces a number of adverse effects including epigastric pain, dyspepsia, nausea, and vomiting. Tolmetin is approximately 99% plasma protein bound, yet does not interfere with concurrent treatment with oral hypoglycemics. Tolmetin has been found to be effective in the treatment of osteoarthritis and rheumatoid arthritis.

Usesinhibits synthesis of prostaglandins and exhibits expressed analgesic, anti-inflammatory, and fever-reducing properties. It is used for relieving weak to moderate pain in rheumatoid arthritis and osteoarthritis.

UsesTolmetine is an NSAID.

General DescriptionTolmetin sodium (Tolectin), is an arylacetic acid derivativewith a pyrrole as the aryl group. This drug is well absorbed and has a relatively short plasma half-life (1 hour). It is recommendedfor use in the management of acute and chronicRA. Its efficacy is similar to aspirin and indomethacin, butwith less frequency of the adverse effects and tinnitus associatedwith aspirin. It does not potentiate coumarin-likedrugs nor alter the blood levels of sulfonylureas or insulin.However, tolmetin, and especially its closely related drug,zomepirac (i.e., with a p-chlorobenzoyl group and an additionalmethyl group on the pyrrole ring), can produce a rarebut fatal anaphylactic reaction because of irreversible bindingof their unstable acyl glucuronides. Zomepirac waswithdrawn from market because it is eliminated only via theester-type, acyl glucuronide. It is possible that tolmetin isless toxic in this regard because it undergoes additional hepaticbenzylic hydroxylation via its p-methyl group and isexcreted as its stable ether glucuronide.

Upstream & downstream products

Upstream raw materials

p-Toluoyl chlorideSodium hydroxide1-METHYLPYRROLE-2-ACETONITRILEAluminum chloride
Additional notes · 1 item

DefinitionChEBI: A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.